Therapy Areas: Cardiovascular
Genentech reports positive Phase II results for enicepatide in type 2 diabetes
22 September 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), on Tuesday reported positive topline Phase II results for enicepatide, an investigationa...
Otsuka ICU Medical recalls 0.9% Sodium Chloride Injection
18 September 2026 - Otsuka ICU Medical LLC, a manufacturer of IV solutions for healthcare providers, announced on Thursday that it is issuing a voluntary recall for one lot of 0.9% SODIUM CHLORIDE Inj...
US FDA grants orphan drug designation for Lundbeck's asedebart
11 September 2026 - Danish biopharmaceutical company H. Lundbeck A/S (CPH: HLUN-B), which focuses on brain health, said on Friday it has received US Food and Drug Administration orphan drug designatio...
Seismic Pharmaceuticals enrols first patient in istaroxime global Phase 3 trial in cardiogenic shock
10 September 2026 - Seismic Pharmaceuticals, a biotechnology company focused on advancing novel treatments for heart failure, announced on Wednesday the enrolment of the first patient in its global Ph...
Ionis partner Novartis reports pelacarsen Phase 3 trial misses primary endpoint
7 September 2026 - RNA therapy company Ionis Pharmaceuticals Inc (Nasdaq: IONS) disclosed on Monday that its partner Novartis reported topline results from the Phase 3 Lp(a)HORIZON study and said pela...
Thryv Therapeutics licenses new class of SGK1 inhibitors, expanding into neurodegenerative disease
4 September 2026 - Thryv Therapeutics Inc, a clinical-stage biopharmaceutical company advancing selective SGK1 inhibitors, announced on Thursday that it has entered into an exclusive, worldwide, royal...